Liposomes as drug delivery systems for the treatment of TB

Nanomedicine

Volumn 6, Issue 8, 2011, Pages 1413-1428

  Pinheiro, Marina ^a   Lcio, Marlene ^a   LiM A , José L F C ^a   Reis, Salette ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

anti TB drugs; liposomes; macrophages; nanomedicine; targeting

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; DOXORUBICIN; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN A; LEVOFLOXACIN; LIPOSOME; NANOCARRIER; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; CHEMOTHERAPY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; DRUG TARGETING; ENCAPSULATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; KAPOSI SARCOMA; LUNG ALVEOLUS MACROPHAGE; PRIORITY JOURNAL; REVIEW; TUBERCULOSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; TUBERCULOSIS;

EID: 80155125245     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.11.122     Document Type: Review

References (99)

1. Sutherland JS, de Jong BC, Jeffries DJ, Adetifa IM, Ota MO. Production of TNF-a, IL-12(p40) and IL-17 can discriminate between active TB disease and latent infection in a west African cohort. PLoS ONE 5(8), E12365 (2010).
2. Hall G, Leff D, Gumbo T. Treatment of active pulmonary tuberculosis in adults: current standards and recent advances. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 29, 1468-1481 (2009).
3. Raviglione MC, Snider DE Jr, Kochi A. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. JAMA 273, 220-226 (1995).
4. Tiwari RP, Tiwari D, Garg SK, Chandra R, Bisen PS. Glycolipids of Mycobacterium tuberculosis strain H37Rv are potencial serological markers for diagnosis of active tuberculosis. Clin. Diagn. Lab. Immunol. 12, 465-473 (2005).
5. Chimote G, Banerjee R. Evaluation of antitubercular drug-loaded surfactants as inhalable drug-delivery systems for pulmonary tuberculosis. J. Biomed. Mater. Res. A. 89, 281-292 (2009).
6. Agrawal AK, Gupta CM. Tuftsin-bearing liposomes in treatment of macrophage-based infections. Adv. Drug Deliver. Rev. 41, 135-146 (2000).
7. Thanyani ST, Roberts V, Siko DGR, Vrey P, Verschoor JA. A novel application of affinity biosensor technology to detect antibodies to mycolic acid in tuberculosis patients. J. Immunol. Methods. 332, 61-72 (2008).
8. Kurmi BD, Kayat J, Gajbhiye V, Tekade RK, Jain NK. Micro- and nanocarrier-mediated lung targeting. Expert Opin. Drug Deliv. 7, 781-794 (2010).
9. Justo OR, Moraes AM. Incorporation of antibiotics in liposomes designed for tuberculosis therapy by inhalation. Drug Deliv. 10, 201-207 (2003).
10. Santos N, Castanho M. Liposomes: has the magic bullet hit the target? Quim. Nova. 25, 1181-1185 (2002).
11. Bowden DH. The alveolar macrophage. Environ. Health Persp. 55, 327-341 (1984).
12. Sosnik A, Carcaboso AM, Glisoni RJ, Moretton MA, Chiappetta D. New old challenges in tuberculosis: potentially effective nanotechnologies in drug delivery. Adv. Drug Deliver. Rev. 62, 547-559 (2010).
13. Deol P, Khuller G, Joshi K. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob. Agents Chemother. 41(6), 1211-1214 (1997).
14. Pieters J. Mycobacterium tuberculosis and the macrophage: maintaining a balance. Cell Host Microbe 3, 399-407 (2008).
15. Gaspar MM, Cruz A, Penha AF et al. Rifabutin encapsulated in liposomes exhibits increased therapeutic activity in a model of disseminated tuberculosis. Int. J. Antimicrob. Agents 31, 37-45 (2008).
16. Krishnan N, Robertson BD, Thwaites G. The mechanisms and consequences of the extra-pulmonary dissemination of Mycobacterium tuberculosis. Tuberculosis 90, 361-366 (2010).
17. Kaufmann SHE. Tuberculosis: back on commentary the immunologists agenda. Immunity 24, 351-357 (2006).
18. Kartmann B, Stenger S, Niederweis M. Porins in the cell wall of Mycobacterium tuberculosis. J. Bacteriol. 181, 6543-6546 (1999).
19. Vyas SP, Kannan ME, Jain S, Mishra V, Singh P. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int. J. Pharm. 269, 37-49 (2004).
20. Bold TD, Ernst JD. Who benefits from granulomas, mycobacteria or host? Cell 136, 17-19 (2009).
21. Saunders BM, Cooper AM. Restraining mycobacteria: role of granulomas in mycobacterial infections. Immunol. Cell Biology 78, 334-341 (2000).
22. Peyron P, Vaubourgeix J, Poquet Y et al. Foamy macrophages from tuberculous patients granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. PLoS Pathog. 4, e1000204 (2008).
23. Co DO, Hogan LH, Kim SI, Sandor M. Mycobacterial granulomas: keys to a long-lasting host-pathogen relationship. Clin. Immunol. 113, 130-136 (2004).
24. Cardona PJ. RUTI: a new chance to shorten the treatment of latent tuberculosis infection. Tuberculosis 86, 273-289 (2006).
25. Guidry TV, Hunter RL Jr, Actor JK. Mycobacterial glycolipid trehalose 6,6-dimycolate-induced hypersensitive granulomas: contribution of CD4+ lymphocytes. Microbiology 153, 3360-3369 (2007).
26. Sundaramurthy V, Pieters J. Interactions of pathogenic mycobacteria with host macrophages. Microbes. Infect. 9, 1671-1679 (2007).
27. Steenwinkel JEM, Vianen W, Kate MT et al. Targeted drug delivery to enhance efficacy and shorten treatament duration in disseminated Mycobacterium avium infection in mice. J. Antimicrob. Chemoth. 60, 1064-1073 (2007).
28. Figueiredo R, Moiteiro C, Medeiros MA et al. Synthesis and evaluation of rifabutin analogs aganist Mycobacterium avium and H37Rv, MDR, and NRP Mycobacterium tuberculosis. Bioorg. Med. Chem. 17, 503-511 (2009).
29. Cardona PJ, Amat I. Origin and development of RUTI, a new therapeutic vaccine against Mycobacterium tuberculosis infection. Arch. Bronconeumol. 42, 25-32 (2006).
30. Ahsan MJ, Samy JG, Dutt KR et al. Design, synthesis and antimycobacterial evaluation of novel 3-substituted-N-aryl-6,7-dimethoxy- 3a,4-dihydro-3H- indeno[1,2-c]pyrazole-2 -carboxamide analogues. Bioorg. Med. Chem. Lett. 21, 4451-4453 (2011).
31. Barry CE, 3rd Blanchard JS. The chemical biology of new drugs in the development for tuberculosis. Curr. Opin. Chem. Biol. 14, 456-466 (2010).
32. Chauhan PM, Sunduru N, Sharma M. Recent advances in the design and synthesis of heterocycles as anti-tubercular agents. Fut. Med. Chem. 2, 1469-1500 (2011).
33. Kantevari S, Yempala T, Surineni G, Sridhar B, Yogeeswari P, Sriram D. Synthesis and antitubercular evaluation of novel dibenzo[b,d]furan and 9-methyl-9H-carbazole derived hexahydro-2H-pyrano[3,2-c]quinolines via Povarov reaction. Eur. J. Med. Chem. (2011).
34. Leibert E, Rom WN. New drugs and regimens for treatment of TB. Expert Rev. Anti Infect. Ther. 8, 801-813 (2010).
35. Li Y, Zhou Y, Ma Y, Li X. Design and synthesis of novel cell wall inhibitors of Mycobacterium tuberculosis GlmM and GlmU. Carbohydr. Res. 346(13), 1714-1720 (2011).
36. Lounis N, Guillemont J, Veziris N, Koul A, Jarlier V, Andries K. [R207910 (TMC207): a new antibiotic for the treatment of tuberculosis]. Med. Mal. Infect. 40, 383-390 (2010).
37. Moraski GC, Markley LD, Hipskind PA et al. Advent of Imidazo[1,2-a] pyridine-3- carboxamides with potent multi- and extended drug resistant antituberculosis activity. ACS Med. Chem. Lett. 2, 466-470 (2011).
38. Mugunthan G, Sriram D, Yogeeswari P, Ravindranathan Kartha KP. Synthesis and biological evaluation of sugar-derived chiral nitroimidazoles as potential antimycobacterial agents. Carbohydr. Res. 346(13), 1760-1766. (2011).
39. Sala C, Hartkoorn RC. Tuberculosis drugs: new candidates and how to find more. Fut. Microbiol. 6, 617-633 (2011).
40. Shi R, Sugawara I. Development of new anti-tuberculosis drug candidates. Tohoku. J. Exp. Med. 221, 97-106 (2010).
41. Speck-Planche A, Scotti MT, de Paulo- Emerenciano V. Current pharmaceutical design of antituberculosis drugs: future perspectives. Curr. Pharm. Des. 16, 2656-2665 (2010).
42. Rodrigues C, Gameiro P, Prieto M, Castro B. Interaction of rifampicin and isoniazid with large unilamellar liposomes: spectroscopic location studies. Biochim. Biophys. Acta. 1620, 151-159 (2003).
43. Owen R, Strasters J, Breyer ED. Lipid vesicles in capillary electrophoretic techniques: characterization of structural properties and associated membrane-molecule interactions. Electrophoresis 26, 735-751 (2005).
44. Balen GP, Martinet CM, Caron G et al. Liposome/water lipophilicity: methods, information content, and pharmaceutical applications. Med. Res. Rev. 24, 299-324 (2004).
45. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J. 19, 311-330 (2005).
46. Dean AS. Liposomal drug delivery. J. Infus. Nurs. 30, 89-95 (2007).
47. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci. 30, 592-599 (2009).
48. Zhang L, Pornpattananangku D, Hu CM, Huang CM. Development of nanoparticles for antimicrobial drug delivery. Curr. Med. Chem. 17, 585-594 (2010).
49. Sanvicens N, Marco MP. Multifunctional nanoparticles - properties and prospects for their use in human medicine. Trends Biotechnol. 26, 425-433 (2008).
50. Bangham AD, Standish MM, Watkins JC. Diffusion of univalent ions across lamellae of swollen phospholipids. J. Mol. Biol. 13, 238-252 (1965).
51. Schroeder A, Kost J, Barenholz Y. Ultrasound, liposomes, and drug delivery: principles for using ultrasound to control the release of drugs from liposomes. Chem. Phys. Lipids 162, 1-16 (2009).
52. Lindner LH, Hossann M. Factors affecting drug release from liposomes. Curr. Opin. Drug Discov. Devel. 13, 111-123 (2010).
53. Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv. Drug Deliver. Rev. 58, 1456-1459 (2006).
54. Bawarski WE, Chidlowsky E, Bharali DJ, Mousa SA. Emerging nanopharmaceuticals. Nanomed-Nanotechnol. 4, 273-282 (2008).
55. Huang YZ, Gao JQ, Liang WQ, Nakagawa S. Preparation and characterization of liposomes encapsulating chitosan nanoparticles. Biol. Pharm. Bull. 28, 387-390 (2005).
56. Koo OM, Rubinstein I, Onyuksel H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomed- Nanotechnol. 1, 193-212 (2005).
57. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed. 1, 297-315 (2006).
58. Williams DF. On the nature of biomaterials. Biomaterials 30, 5897-5909 (2009).
59. Barratt G, Bretagne S. Optimizing efficacy of amphotericin B through nanomodification. Int. J. Nanomed. 2, 301-313 (2007).
60. Agarwal A, Kandpal H, Gupta H, Singh N, Gupta C. Tuftsin-bearing liposomes as rifampin vehicles in treatment of tuberculosis in mice. Antimicrob. Agents Chemother. 38, 588-593 (1994).
61. Vyas SP, Khatri K. Liposome-based drug delivery to alveolar macrophages. Expert Opin. Drug Deliv. 4, 95-99 (2007).
62. Pandey R, Khuller GK. Antitubercular inhaled therapy: opportunities, progress and challenges. J. Antimicrob. Chemoth. 55, 430-435 (2005).
63. Resnik DB, Tinkle SS. Ethics in nanomedicine. Nanomedicine (Lond.) 2, 345-350 (2007).
64. Hoet P, Legiest B, Geys J, Nemery B. Do nanomedicines require novel safety assessments to ensure their safety for long-term human use? Drug Safety 32, 625-636 (2009).
65. Pandey R, Khuller GK. Nanotechnology based drug delivery system(s) for the management of tuberculosis. Indian J. Exp. Biol. 44, 357-366 (2006).
66. Deol P, Khuller GK. Lung specific stealth liposomes: stability, biodistribution and toxicity of liposomal antitubercular drugs in mice. Biochim. Biophys. Acta. 1334, 161-172 (1997).
67. Pison U, Welte T, Giersing M, Groneberg DA. Nanomedicine for respiratoy diseases. Eur. J. Pharmacol. 533, 341-350 (2006).
68. Gill S, Lbenberg R, Ku T, Azarmi S, Roa W, Prenner EJ. Nanoparticles: characteristics, mechanisms of action, and toxicity in pulmonary drug delivery - a review. J. Biomed. Nanotechnol. 3, 107-119 (2007).
69. Andrade F, Videira M, Ferreira D, Sarmento B. Nanocarriers for pulmonary administration of peptides and therapeutic proteins. Nanomedicine (Lond.) 6, 123-141 (2011).
70. Medina C, Santos-Martinez MJ, Radomski A, Corrigan OI, Radomski MW. Nanoparticles: pharmacological and toxicological significance. Brit. J. Pharmacol. 150, 552-558 (2007).
71. Surendiran A, Sandhiya S, Pradhan SC, Adithan C. Novel applications of nanotechnology in medicine. Indian. J. Med. Res. 130, 689-701 (2009).
72. El-Ridy MS, Mostafa DM, Shehab A, Nasr EA, Abd ES. Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis. Int. J. Pharm. 330, 82-88 (2007).
73. Mobley C, Hochhaus G. Pharmacokinetic considerations in the design of pulmonary drug delivery systems for glucocorticoids. In:Drug Targeting Technology: Physical, Chemical, Biological Methods. Volume 115 (1st Edition). Schreier H (Ed.). New York, Informa Healthcare 72-73 (2001).
74. Dhillon J, Fielding R, Adler-Moore J, Goodael RL, Mitchison D. The activity of low-clearance liposomal amikacin in experimental murine tuberculosis. J. Antimicrob. Chemoth. 48, 869-876 (2001).
75. Pandey R, Sharma S, Khuller GK. Nebulization of liposome encapsulated antitubercular drugs in guinea pigs. Int. J. Antimicrob. Ag. 24, 93-94 (2004).
76. Huynh NT, Passirani C, Saulnier P, Benoit JP. Lipid nanocapsules: a new platform for nanomedicine. Int. J. Pharm. 379, 201-209 (2009).
77. Irache JM, Salman HH, Gamazo C, Espuelas S. Mannose-targeted systems for the delivery of therapeutics. Expert Opin. Drug Deliv. 5, 703-724 (2008).
78. Labana S, Pandey R, Sharma S, Khuller GK. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. Int. J. Antimicrob. Ag. 20, 301-304 (2002).
79. Chono S, Kaneko K, Yamamoto E, Togami K, Morimoto K. Effect of surface-mannose modification on aerosolized liposomal delivery to alveolar macrophages. Drug. Dev. Ind. Pharm. (2009).
80. Wijagkanalan W, Kawakami S, Takenaga M, Igarashi R, Yamashita F, Hashida M. Efficient targeting to alveolar macrophages by intratracheal administration of mannosylated liposomes in rats. J. Control. Release 125, 121-130 (2008).
81. Zaru M, Mourtas S, Klepetsanis P, Fadda AM, Antimisiaris SG. Liposomes for drug delivery to the lungs by nebulization. Eur. J. Pharm. Biopharm. 67, 655-666 (2007).
82. Ravaoarinoro M, Toma E, Agbaba O, Morisset R. Efficient entrapment of amikacin and teicoplanin in liposomes. J. Drug Target. 1, 191-195 (1993).
83. Maurer N, Fenske DB, Cullis PR. Developments in liposomal drug delivery systems. Expert Opin. Biol. Ther. 1, 923-947 (2001).
84. Korf J, Stoltz A, Verschoor J, De Baetselier P, Grooten J. The Mycobacterium tuberculosis cell wall component mycolic acid elicits pathogen-associated host innate immune responses. Eur. J. Immunol. 35, 890-900 (2005).
85. Andersen CA, Rosenkrands I, Olsen AW et al. Novel generation mycobacterial adjuvant based on liposome-encapsulated monomycoloyl glycerol from Mycobacterium bovis bacillus Calmette-Guerin. J. Immunol. 183, 2294-2302 (2009).
86. Dascher CC, Hiromatsu K, Xiong X et al. Immunization with a mycobacterial lipid vaccine improves pulmonary pathology in the guinea pig model of tuberculosis. Int. Immunol. 15, 915-925 (2003).
87. Christensen D, Agger EM, Andreasen LV, Kirby D, Andersen P, Perrie Y. Liposome-based cationic adjuvant formulations (CAF): past, present, and future. J. Liposome Res. 19, 2-11 (2009).
88. Cui Z, Mumper RJ. Microparticles and nanoparticles as delivery systems for DNA vaccines. Crit. Rev. Ther. Drug Carrier Syst. 20, 103-137 (2003).
89. Koga H, Miyazaki Y, Kohno S, Hara K. A drug delivery system and biological response modifiers for the treatment of mycobacterial infection. Kekkaku 69, 113-118 (1994).
90. Okada M. Novel vaccines against tuberculosis. Kekkaku 81, 745-751 (2006).
91. Lalloo UG, Ambaram A. New antituberculous drugs in development. Curr. HIV/AIDS Rep. 7, 143-151 (2010).
92. Jain KK. Nanomedicine: application of nanobiotechnology in medical practice. Med. Princ. Pract. 17, 89-101 (2008).
93. Azarmi S, Roa W, Loebenberg R. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv. Drug Deliver. Rev. 60, 863-875 (2008).
94. Comas I, Gagneux S. The past and the future of tuberculosis research. PLoS Pathog. 5, (2009).
95. Ginsberg AM. Tuberculosis drug development: progress, challenges, and the road ahead. Tuberculosis 90, 162-167 (2010).
96. Nuermberger EL, Spigelman MK, Yew WW. Current development and future prospects in chemotherapy of tuberculosis. Respirology 15, 764-778 (2010).
97. Pai M, Minion J, Steingart K, Ramsay A. New and improved tuberculosis diagnostics: evidence, policy, practice, and impact. Curr. Opin. Pulm. Med. 16, 271-284 (2010).
98. Traini D, Young PM. Delivery of antibiotics to the respiratory tract: an update. Expert Opin. Drug Deliv. 6, 897-905 (2009).
99. Craven DE, Steger KA, Hirschorn LR. Nosocomial colonization and infection in persons infected with human immunodeficiency virus. Infect. Control Hosp. Epidemiol. 17, 304-318 (1996).